Physician profile
Michael A Steck
NPI 1194856567
$6,605.36
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $778 · 2021: $1,142 · 2022: $1,358 · 2023: $1,566 · 2024: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,784.80 | 2019-2024 | Acuvue |
| Alcon Vision LLC | $1,086.05 | 2019-2024 | Total30 |
| Bausch & Lomb Americas INC. | $1,021.96 | 2022-2024 | Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $820.61 | 2019-2021 | |
| Coopervision INC. | $203.76 | 2019-2023 | Myday Contact Lens |
| Sight Sciences, INC. | $140.00 | 2022 | |
| Shire North American Group INC | $125.00 | 2019 | |
| Horizon Therapeutics Plc | $114.55 | 2022 | |
| Sun Pharmaceutical Industries INC. | $113.91 | 2020 | |
| Astellas Pharma US INC | $106.09 | 2024 | Izervay |
| Abbvie INC. | $64.71 | 2023 | Xen Glaucoma Treatment System |
| Lensar, INC. | $23.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Steck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.